A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial To Study The Efficacy And The Safety Of The Early Administration Of Somatostatin (Ucb) 12 Mg/24 H IV Infusion And Two IV Boluses Of 250 Mcg During 72 Hours In The Treatment Of Subjects With Acute Severe Upper Gastrointestinal Bleeding (UGIB) With Suspicion Of Peptic Ulcer Bleeding [The PUB Study]
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Somatostatin (Primary)
- Indications Bleeding ulcer
- Focus Adverse reactions; Therapeutic Use
- Acronyms PUB
- 18 Sep 2012 Biomarkers information updated
- 20 Oct 2009 Actual end date (Oct 2005) added as reported by ClinicalTrials.gov.
- 06 Jun 2007 Status changed from in progress to completed.